Taisuke Izumi

Current HIV/AIDS-Related Research Activities:

I am an experienced researcher in the field of HIV/AIDS, with over a decade of dedication to understanding the fundamental mechanisms of virus persistence. My work, strongly centered around host-virus interactions and innovative antiretroviral therapies, has contributed significantly to the HIV research landscape.

A cornerstone of our achievements has been the identification of a crucial structural feature of the anti-HIV host protein, APOBEC3G. This key finding has fostered advancements in in-silico drug development, propelling forward the creation of new antiretroviral therapies. It underscores the promising role computational modeling and simulation techniques can play in expediting the drug discovery process.

In our relentless pursuit of HIV research, my team and I have pioneered a groundbreaking single-virion imaging system via fluorescence microscopy. This innovative tool allows real-time observation and analysis of individual virus particles, enhancing our understanding of viral maturation and dissemination processes significantly.

Currently, we are focusing on an evolved "kick-and-kill" strategy (Kick-and-kill 2.0), aiming for an HIV cure. This approach utilizes latency-reversing agents (LRAs) to reactivate the viral reservoir, setting the stage for the elimination of latently infected cells. Intriguingly, our recent studies reveal that certain FDA-approved cancer therapy drugs can serve dual purposes - effective latent cell reactivation and boosting of the immune response against reactivated cells. This multifaceted approach will enable us to make the clearance of latently infected cells.

Moving forward, our research will probe deeper into the complex molecular mechanisms underpinning persistent virus infections. Our ultimate goal remains the discovery of a functional cure for chronic infectious diseases, with a primary emphasis on HIV/AIDS. We stand firm in our commitment to scientific excellence and our mission to transform the lives of those affected by HIV/AIDS.